INSYS Therapeutics to Record a Minimum Liability f
Post# of 301275
PHOENIX, Oct. 29, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY ) (“INSYS” or “the company”), today made the following statement about the Department of Justice (DOJ) investigation.
In connection with our cooperation with the DOJ, we have been engaged in discussions with the government regarding a resolution of potential liability exposure. As of Sept. 30, 2017, $150 million has been accrued, which represents our best estimate of the minimum liability exposure we expect to pay over five years. In addition, we did not recognize any tax benefit relating to this accrual because at the time we did not have sufficient information to make a determination regarding tax deductibility.
This estimate reflects a minimum exposure at which management has determined a willingness to settle these matters. The DOJ has not accepted management’s offer, and there can be no assurance that future discussions with the government to resolve these matters will be successful, that the approvals we need will be obtained or that any potential settlement will be agreed to on terms and conditions acceptable to us or the DOJ. We are unable to predict when these matters will be resolved or what further action, if any, the government will take in connection with them. Based on the ongoing uncertainties and potentially wide range of outcomes associated with any potential resolution of the matter under investigation by the DOJ, the ultimate amount of potential liability may materially exceed the $150 million accrual we have established.
About INSYS INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life. Using proprietary spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing commercial products. INSYS currently markets SUBSYS ® (fentanyl sublingual spray), CII, and SYNDROS ® (dronabinol) oral solution, CII, a proprietary, orally administered liquid formulation of dronabinol. INSYS is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with a significant unmet need.
SUBSYS ® and SYNDROS ® are trademarks of INSYS Development Company, Inc., a subsidiary of INSYS Therapeutics, Inc.
NOTE: All trademarks and registered trademarks are the property of their respective owners.
Forward-Looking Statements This news release contains forward-looking statements. Forward looking statements are based on management’s expectations and assumptions as of the date of this news release; actual results may differ materially from those in these forward-looking statements as a result of various factors, many of which are beyond our control. These factors include, but are not limited to, risk factors described in our filings with the United States Securities and Exchange Commission, including those factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended Dec. 31, 2016 and subsequent updates that may occur in our Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date of this news release, and we undertake no obligation to publicly update or revise these statements, except as may be required by law.
CONTACT:
Media Relations Joe McGrath Senior Director, Corporate Communications INSYS Therapeutics 480-500-3101 jmcgrath@insysrx.com
Investor Relations Jackie Marcus or Chris Hodges Alpha IR Group 312-445-2870 INSY@alpha-ir.com